Autophagy as a therapeutic mechanism to kill drug-resistant cancer cells
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Autophagy as a therapeutic mechanism to kill drug-resistant cancer cells
Authors
Keywords
-
Journal
ANTI-CANCER DRUGS
Volume -, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-10-16
DOI
10.1097/cad.0000000000001549
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options
- (2023) Georgia Gomatou et al. Cancers
- Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC
- (2023) Weiwei Peng et al. Frontiers in Oncology
- Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells
- (2023) Laurence Booth et al. ANTI-CANCER DRUGS
- Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib
- (2021) Paul Dent et al. BIOCHEMICAL PHARMACOLOGY
- Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling
- (2020) Paul Dent et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate]
- (2020) Paul Dent et al. CELLULAR SIGNALLING
- Irreversible kinase inhibitors targeting to cysteine residues and their applications in cancer therapy
- (2020) Debasis Das et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer
- (2020) Laurence Booth et al. BIOCHEMICAL PHARMACOLOGY
- Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells
- (2019) Paul Dent et al. ONCOGENE
- Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma
- (2019) Sarah W. Gordon et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Emerging role of the Jun N-terminal kinase interactome in human health
- (2018) Xiao-Xi Guo et al. CELL BIOLOGY INTERNATIONAL
- Neratinib augments the lethality of [regorafenib + sildenafil]
- (2018) Laurence Booth et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
- (2017) Laurence Booth et al. Oncotarget
- [Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration
- (2017) Laurence Booth et al. Oncotarget
- Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function
- (2016) Laurence Booth et al. Oncotarget
- Phase I study of pemetrexed with sorafenib in advanced solid tumors
- (2016) Andrew Poklepovic et al. Oncotarget
- [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling
- (2016) Laurence Booth et al. Oncotarget
- Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo
- (2016) Laurence Booth et al. Oncotarget
- Nexavar/Stivarga and Viagra Interact to Kill Tumor Cells
- (2015) Mehrad Tavallai et al. JOURNAL OF CELLULAR PHYSIOLOGY
- GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases
- (2015) Jane L. Roberts et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling
- (2012) M. Danielle Bareford et al. CANCER BIOLOGY & THERAPY
- Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: Growth inhibition, quiescence, and recovery
- (2012) Brian I. Carr et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells
- (2011) M. D. Bareford et al. CANCER RESEARCH
- Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation
- (2010) Margaret A. Park et al. CANCER BIOLOGY & THERAPY
- Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+-De novo Ceramide-PP2A-Reactive Oxygen Species-Dependent Signaling Pathway
- (2010) M. A. Park et al. CANCER RESEARCH
- BCL-2 Family Inhibitors Enhance Histone Deacetylase Inhibitor and Sorafenib Lethality via Autophagy and Overcome Blockade of the Extrinsic Pathway to Facilitate Killing
- (2009) A. P. Martin et al. MOLECULAR PHARMACOLOGY
- Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95-Dependent and -Independent Mechanisms
- (2009) T. Walker et al. MOLECULAR PHARMACOLOGY
- Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation
- (2008) G. Zhang et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now